SPIRE-LL
STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS
- Stage
- klaar
- Medicine
- PF-04950615 (PCSK9)
- Population
- Primaire preventie coronairlijden
- Phase
- III
- First Patient In
- 31 January 2015
- Last Patient In
- 31 May 2015
- Last Patient Last Visit
- 1 September 2016
Study Director
